Initial antiretroviral therapy: The dilemmas ahead

被引：0
|
作者：
Arribas, Jose R. [1 ]
机构：
[1] Hosp Univ La Paz, Internal Med Serv, HIV Unit, IdiPAZ, Madrid, Spain
来源：
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2013年 / 31卷 / 02期
关键词：
CO-FORMULATED ELVITEGRAVIR; NON-INFERIORITY TRIAL; NAIVE ADULTS; DOUBLE-BLIND; HIV-1; INFECTION; TENOFOVIR; PHASE-3; EMTRICITABINE; EFAVIRENZ; RILPIVIRINE;
D O I：
10.1016/j.eimc.2012.07.011
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
[No abstract available]
引用
收藏
页码：68 / 70
页数：3
相关论文
共 50 条
  • [1] Antiretroviral therapy: dolutegravir sets SAIL(ING)
    Boyd, Mark A.
    Donovan, Basil
    LANCET, 2013, 382 (9893) : 664 - 666
  • [2] Advances in antiretroviral therapy
    Arribas, Jose R.
    Eron, Joseph
    CURRENT OPINION IN HIV AND AIDS, 2013, 8 (04) : 341 - 349
  • [3] Quad's in it for antiretroviral therapy?
    Schrijvers, Rik
    Debyser, Zeger
    LANCET, 2012, 379 (9835) : 2403 - 2405
  • [4] Factors Associated With the Selection of Initial Antiretroviral Therapy From 2009 to 2012
    Saag, Michael S.
    Westfall, Andrew O.
    Cole, Stephen R.
    Mathews, William C.
    Drozd, Daniel R.
    Mayer, Kenneth H.
    Burkholder, Greer A.
    Kitahata, Mari
    Maiese, Eric M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 (01) : 60 - 64
  • [5] Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?
    Kelly, Sean G.
    Masters, Mary Clare
    Taiwo, Babafemi O.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2019, 33 (03) : 681 - +
  • [6] Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy
    Di Biagio, Antonio
    Cozzi-Lepri, Alessandro
    Prinapori, Roberta
    Angarano, Gioacchino
    Gori, Andrea
    Quirino, Tiziana
    De Luca, Andrea
    Costantini, Andrea
    Mussini, Cristina
    Rizzardini, Giuliano
    Castagna, Antonella
    Antinori, Andrea
    Monforte, Antonella d'Arminio
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (03) : 263 - 271
  • [7] Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy
    Javier Blasco, Antonio
    Ramon Arribas, Jose
    Clotet, Bonaventura
    Domingo, Pere
    Gonzalez-Garcia, Juan
    Carlos Lopez-Bernaldo, Juan
    Llibre, Josep M.
    Lozano, Fernando
    Podzamczer, Daniel
    Miguel Santamaria, Juan
    Tuset, Montserrat
    Zamora, Laura
    Lazaro, Pablo
    Gatell, Josep M.
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2011, 29 (10): : 721 - 730
  • [8] Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults
    Javier Blasco, Antonio
    Llibre, Josep M.
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Knobel, Hernando
    Lozano, Fernando
    Podzamczer, Daniel
    Pulido, Federico
    Rivero, Antonio
    Tuset, Montserrat
    Lazaro, Pablo
    Gatell, Josep M.
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2015, 33 (03): : 156 - 165
  • [9] Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013
    Javier Blasco, Antonio
    Llibre, Josep M.
    Ramon Arribas, Jose
    Boix, Vicente
    Clotet, Bonaventura
    Domingo, Pere
    Gonzalez-Garcia, Juan
    Knobel, Hernando
    Carlos Lopez, Juan
    Lozano, Fernando
    Miro, Jose M.
    Podzamczer, Daniel
    Miguel Santamaria, Juan
    Tuset, Montserrat
    Zamora, Laura
    Lazaro, Pablo
    Gatell, Josep M.
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2013, 31 (09): : 568 - 578
  • [10] Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
    Estrada, Vicente
    Gorgolas, Miguel
    Pena, Jose A.
    Tortajada, Elena
    Castro, Antonio
    Presa, Maria
    Oyaguez, Itziar
    PHARMACOECONOMICS-OPEN, 2022, 6 (03) : 415 - 424
12345